Search

Your search keyword '"Yanai, Henit"' showing total 493 results
Start Over Author "Yanai, Henit"
493 results on '"Yanai, Henit"'

5. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

Author

Gornet, Jean-Marc, Beaugerie, Laurent, Shaji, Sebastian, Peyrin-Biroulet, Laurent, Reimund, Jean-Marie, Hebuterne, Xavier, Amiot, Aurélien, Armelao, Franco, Blanc, Pierre, Papi, Claudio, De Chambrun, Guillaume Pineton, Roblin, Xavier, Chu, Karmiris, Konstantinos, Shariq, Sohail, Viazis, Nikolaos, Limdi, Jimmy, Eder H, Piotr, Michalopoulos, Georgios, Bell, Andrew, Biancone, Livia, Dewitte, Marie, Mazhar, Zia, Franchimont, Denis, Nancey, Stephane, Macaigne, Gilles, Principi, Maria Beatrice, Fumery, Mathurin, Parkes, Gareth, Valats, Jean-Christophe, Doherty, Glen, Bouguen, Guillaume, Molnar, Tamás, Tsai, Hersin, Gangi, Mohsin, Pedersen, Natalia, Heluwaert, Frédéric, Shenderey, Richard, Zeissig, Sebastian, Butterworth, Jeffrey, Castiglione, Fabiana, Corless, Lynsey, Zallot, Camille, Baert, Filip, Singh, Salil, Sonwalkar, Sunil, Clayton, Elizabeth, Rahier, Jean-François, Vani, Deven, Bellaiche, Guy, De Vos, Martine, Kirchgesner, Julien, Kopylov, Uri, Lobaton, Triana, Locher, Christophe, Mantzaris, Gerassimos, Abouda, George, Smith, Katie, Sprakes, Michael, Theodoropoulou, Angeliki, Wesley, Emma, Bonnet, Joëlle, Elphick, David, Gilletta, Cyrielle, Gordon, John, Laharie, David, Nakad, Antoine, Orlando, Ambrogio, Dubois, Patrick, Hasselblatt, Peter, Michiels, Christophe, Preston, Cathryn, Staicu, Anca, Vuitton, Lucine, Kaassis, Mehdi, Speight, Ally, Ghosh, Deb, Löwenberg, Mark, Mathieu, Nicolas, Pelletier, Anne-Laure, Phillips, Anne, Magro, Fernando, Altwegg, Romain, Avni, Irit, biron, Landy, Jonathon, Nachury, Maria, Shenoy, Achuth, Trang, Caroline, Abitbol, Vered, Bamias, Georgios, Farkas, Klaudia, Maaser, Christian, Shitrit, Ariella, Siegmund, Britta, Filippi, Jérôme, O'morain, Colm, Yanai, Henit, Costes, Laurent, Hobday, David, Szepes, Zoltán, Calabrese, Emma, Dallal, Helen, Fung, Michael, Ramadas, Arvind, Baburajan, Bijay, Koss, Konrad, Barberis, Christophe, Buisson, Anthony, Amil, Morgane, Balestrieri, Paola, Johnson, Matthew, Tzouvala, Maria, Viennot, Stéphanie, Nagy, Ferenc, Thompson, Nick, Alric, Laurent, Samuel, Sunil, Bourrier, Anne, Chanteloup, Elise, Del Tedesco, Emilie, Harbord, Marcus, Lobo, Alan, Myers, Sally, Pollok, Richard, Ahmad, Tariq, Chaudhary, Rakesh, Karakoidas, Christos, Soliman, Ashraf, Stefanescu, Carmen, Theocharis, Georgios, Branden, Stijn Vanden, Beltran, Belén, Bouhnik, Yoram, Bourreille, Arnaud, Branco, Joana, Colleypriest, Ben, Eliakim, Rami, Knight, Paul, O'toole, Aoibhlinn, Robles, Virgina, Triantafyllou, Konstantinos, Bosca, Marta Maia, Lambrecht, Guy, Mosquera, Lucia Marquez, Panter, Simon, Pappa, Aikaterini, Simon, Marion, Sivaji, Ganesh, Bellanger, Christophe, Belle, Arthur, Borruel, Natalia, Egan, Laurence, Peeters, Harald, Sharpstone, Daniel, Arasaradnam, Ramesh, Benitez, José Manuel, Dahlerup, Jens Frederik, Giouleme, Olga, Gisbert, Javier P., Helwig, Ulf, Minguez, Miguel, Tsironi, Eftychia, Variola, Angela, Allen, Patrick, Boivineau, Lucille, Cole, Andy, Dib, Nina, Gomollon, Fernando, Johnston, Richard, Katsanos, Konstantinos, Kennedy, Nick, Kiszka-Kanowitz, Marianne, Marin-Jimenez, Ignacio, Miheller, Pál, Nos, Pilar, Saraj, Othman, Vinter-Jensen, Lars, Zittan, Eran, Baudry, Clotilde, Calvet, Xavier, Cazelles-Boudier, Marie-Christine, Coenegrachts, Jean-Louis, Cullen, Garret, Daperno, Marco, Dhar, Anjan, Gerard, Romain, Jensen, Nanna, Maharshak, Nitsan, Mcalindon, Mark, Mcloughlin, Simon, Parkes, Miles, Patel, Kamal, Peixoto, Armando, Polymeros, Dimitrios, Portela, Francisco, Rocca, Rodolfo, Seksik, Philippe, Subramanian, Sreedhar, Tennenbaum, Ruth, Atreya, Raja, Bachmann, Oliver, Berger, Arthur, Bor, Renáta, Buckley, Maire, Carpio, Daniel, Chaparro, María, Costa, Francesco, Domenech, Eugeni, Esteve, Maria, Foley, Stephen, Guardiola, Jordi, Koutroubakis, Ioannis, Kuehbacher, Tanja, Landman, Cécilia, Lavagna, Alessandro, Manceñido, Noemí, Mañosa, Míriam, Martín-Arranz, Maria Dolores, Plastaras, Laurianne, Scribano, Maria Lia, Sengupta, Subhasish, Teich, Nils, Tran-Minh, My-Linh, Zampeli, Evanthia, Amininejad, Leila, Arroyo, Teresa, Attar, Alain, Backman, Ann-Sofie, Bálint, Anita, Beckly, John, Ben Horin, Shomron, Bernardo, Sónia, Caillo, Ludovic, Caron, Bénédicte, Shanika de Silva, María, FábiáN, Anna, Fiorino, Gionata, Gutierrez, Ana, Lahat, Adi, Masmoudi, Mohamed, Mendolaro, Marco, Muls, Vinciane, Poullenot, Florian, Probert, Christopher, Reenaers, Catherine, Rutka, Mariann, Sarwari, Zaman, Sayer, Joanne, Sicilia, Beatriz, Sousa, Helena, van Kemseke, Catherine, Zabana, Yamile, Astegiano, Marco, Banim, Paul, Bettenworth, Dominik, Boualit, Médina, Brodersen, Jacob Broder, Christidou, Angeliki, Cooney, Rachel, Pinto, João Cortez, Cravo, Portugal Marília, Cremer, Anneline, Danese, Silvio, di Sabatino, Antonio, Fallingborg, Jan, Ferronato, Antonio, Planella, Esther Garcia, Gupta, Sanjay, Halfvarson, Jonas, Israeli, Eran, Kestenbaum, Samantha, Larsen, Lone, Macken, Elisabeth, Mathou, Nicoletta, Milassin, Ágnes, Pofelski, Joanna, Ricci, Chiara, Rodriguez-Moranta, Francisco, Schmidt-Lauber, Martin, Shaw, Ian, Soares, Marta, Soliman, Heithem, Triantos, Christos, Zografos, Konstantinos, Agrawal, Anurag, Armuzzi, Alessandro, Aubourg, Alexandre, Acosta, Manuel Barreiro-de, Barrio, Jesús, Bergemalm, Daniel, Bermejo, Fernando, Bodini, Giorgia, Bohr, Johan, Bossuyt, Peter, Christodoulou, Dimitrios, Claessens, Christophe, Collins, Paul, de Francisco, Ruth, Garcia, Santiago, Georgopoulos, Sotirios, Goutorbe, Felix, Kalantzis, Chrisostomos, Kourikou, Anastasia, Mace, Vincent, Malamut, Georgia, Ministro, Paula, Larmurier, Isabelle Nion, Ricart, Elena, Serrero, Mélanie, Sheridan, Juliette, Weimers, Petra, Andersen, Vibeke, Arroja, Bruno, Bokemeyer, Bernd, Bujanda, Luis, Degand, Thibault, Eriksson, Carl, Garceau, Cécile, Glerup, Henning, Goren, Idan, Jackson, Lucina, Koch, Stéphane, Mesonero, Francisco, Ordas, Ingrid, Riviere, Pauline, Saibeni, Simone, Soares, João, Tavernier, Noémie, Theede, Klaus, Ungar, Bella, Bästlein, Elke, Gasbarrini, Antonio, Protopapas, Andreas, Reindl, Wolfgang, Bossa, Fabrizio, Hart, Ailsa, Heil, Franz-Josef, O'Connor, Anthony, Oldenburg, Bas, Pastorelli, Luca, Stephen patchett, Ramakrishnan, Subramaniam, de Caestecker, John, Echarri, Ana, Kevans, David, Büning, Jürgen, Coelho, Rosa, Jansen, Jeroen, Koslowski, Benjamin, Wells, Christopher, Ceballos, Daniel, König, Ingrid, Padmanabhan, Hari, Patani, Timi, Qureshi, Raheel, Zagorowicz, Edyta, Allez, Matthieu, Archavlis, Emmanouil, Bonnet, Delphine, Guidi, Luisa, Mcnamara, Deirdre, Vernia, Piero, Weidenhiller, Michael, Alon, Lang, Boysen, Trine, Delattre, Charlotte, Farrell, Richard, Krüger, Rolf-Achim, Paupard, Thierry, Vind, Ida, Caprioli, Flavio, Gancho, Vladimir, Quentin, Vincent, Avidan, Benjamin, D’Haens, Geert, Mccarthy, Jane, Snook, Jonathon, Soufleris, Konstantinos, Zerbib, Frank, Carter, Dan, Depla, Annekatrien, Eisenbach, Thomas, Fries, Walter, Grammatikos, Nikolaos, Ilegems, Saskia, Lopez-Sanroman, Antonio, Moreau, Jacques, Riegler, Gabriele, Rietdijk, Svend, Rocha, Marta, Rosa, Isabelle, Ryan, Barbara, Yeremenko, Yelena, Boruchowicz, Arnaud, Damião, Filipe, Laoudi, Foteini, Lügering, Andreas, Macarri, Giampiero, Thomopoulos, Konstantinos, Barros, Luísa, Blixt, Thomas, Garros, Aurélien, Khorrami, Sam, Sokol, Harry, Sturm, Andreas, Livovsky, Dan, Maul, Jochen, Miks, Heinrich, Papadopoulos, Vasileios, Schmidt, Carsten, Snir, Yifat, Svenningsen, Lise, Ahmed, Wafaa, Broitman, Yelena, Cuillerier, Emmanuel, Kant, Prashant, Leyden, Jan, Lichtenstein, Lev, Lopes, Susana, Martineau, Chloé, Mulcahy, Hugh, Schweitzer, Axel, Van Schaik, Fiona, Banai, Hagar, Danion, Pauline, Dulery, Charlotte, Fidder, Herma, Gay, Claire, Hagege, Hervé, Harnois, Florence, Jørgensen, Søren Peter, Müller-Ziehm, Jens, Oikonomou, Michail, Palmela, Carolina, Schulze/Röske, Jörg, Smith, Mark, Thurm, Tamar, Bresso, Francesca, Brixi, Hedia, Jones, John, Macmathuna, Padraig, Painchart, Claire, Ron, Yulia, Vester-Andersen, Marianne, Alexandrino, Gonçalo, Börner, Norbert, Cardoso, Mariana, Chagas, Cristina, Dignaß, Axel, Dotan, Iris, Hedin, Charlotte, Karatzas, Pantelis, Kasapidis, Panagiotis, Palatka, Károly, Sakizlis, Georgios, Wilson, Ana, Bosanko, Nick, Caldeira, Paulo, Gagniere, Charlotte, Libier, Louise, Meunier, Camille, Moog, Gero, Pasquion, Audrey, Pica, Roberta, Akbar, Ayesha, Arab, Nadia, Cadiot, Guillaume, Carvalho, João, Charpignon, Claire, Fellermann, Laus, Fishman, Sigal, Fraser, Gerald, Gluck, Nathan, Hoesl, Mark, Kierkus, Jarosław, Klopocka, Maria, Arranz, Eduardo Martin, Menchen, Luis, Nikolaus, Susanna, Petrache, Anca, Ponsioen, Cyriel, Riestra, Sabino, Robledo, Pilar, Rodriguez, Cristina, Samer, Misheal, Tischer, Matthias, Wypych, Joanna, Baudon, Julien, Bezzio, Cristina, Boschetti, Gilles, Burisch, Johan, Creed, Tom, Demarzo, Maria Giulia, Festa, Stefano, Figueroa, Andrés, Julsgaard, Mette, Navarro, Pablo, Perez-Galindo, Pablo, Rouillon, Cléa, Sablich, Emanuele, Tosca, Joan, Vidon, Mathias, Vidon, Marine, Vitte, René-Louis, Wampach, Anne, Baumann, Cédric, Urmes, Isabelle Clerc, Rousseau, Hélène, Borie, Marc, Uzzan, Mathieu, Chatten, Kelly, Peter, Rimmer, Tariq, Iqbal, Cossignani, Marta, Cañete, Fiorella, Holvoet, Tom, Krasz, Susanne, Dias, Sandra, Abalia, Hadas, Abaza, Aziza, Abramovich, Gal, Ackzell, Ingrid, Adams, Carol, Addleton, Catherine, Alfambra, Erika, Algaba, Alicia, Allcock, Clare, Allison, Joanna, Amouriaux, Karine, Anderson, Julie, Anderson, Emma, Appelmans, Saskia, Armstrong, Lisa, Atkins, Stacey, Attaran-Bandarabadi, Masoumeh, Bailey, Yvonne, Bardot, Stephanie, Beck, Natasha, Bennett, Lillie, Bergfeld, Jonathan Phil, Berkane, Ramdane, Boey, Hanne, Bowlas, Louise, Bradley-Potts, Joanne, Brear, Tracy, Bretlander-Peters, Nicole, Brown, Ellen, Brown, Johanna, Buckingham, Elizabeth, Buellens, Katrien, Bull, Rhian, Burke, Maura, Burns, Leighanne, Burton, Julie, Bwalya, Agness, Cabanas, Karine, Callaghan, Muriel, Camou, Océane, Campbell, Debbie, Capoferro, Elvira, Carnahan, Mandy, Carnio, Cornelia, Carter, Anne, Clack, Concetta Casali, Chedouba, Leïla, Cipriano, Bessie, Claeys, Sophie, Closset, Manon, Coban, Dilek, Cococcia, Sara, Coe, Carolann, Cole, Helen, Collet, Emilie, Collins, Kayleigh, Combes, Isabelle, Connor, Emma, Constantin, Kathryn, Cooke, Susan, Cornet, Nathanaëlle, Corrihons, Estelle, Corsino, Pilar, Cortaville, Rosie, Cotterill, Donna, Cowton, Amanda, Cox, Harriet, Cripps, Viktoria, Crowder, Amanda, Cukier, Tzufit, Daniel, Amelia, Dawe, Chris, de Haan, Jose, Croix, Rosanna de la, Dejonckheere, Evva, Villanegro, Juan Delare, Delaval, Guillaume, Delliponti, Mariangela, Delommez, Aude, Detry, Emilie, Dhanaratne, Melanie, Galan, Laura Diez, Dodel, Marie, Dooks, Emma, Du Cheyron, Joseph, Duane, Linda, Vulgo Cochran, Jennifer Dulling, Dyer, Simona, Dymond, Harvey, Ekblad, Charlotte, Elliott, Kerry, Emmerson, Ingrid, Eugene-Jolchine, Irène, Fleming, Lorna, Fletcher, Eve, Ford, Sarah, Forshaw, Greg, Foulds, Angela, Francois, Caroline, Fuge, Nicole, Gafni, Gal, Ganon, Miri, Nuñez, Olga Garcia, Ramirez, Laura Garcia, Gelder, Sophie, Gettkowski, Raimonda, Gilardi, Daniela, Giuffrida, Paolo, Gobert, Vincent, Godden, Jo, Godwin, Nuala, Goulden, Kay, Graham, Sharon, Green, Charlotte, Green, Marie, Gueye, Aboubakar, Guler, Tuba, Gustavsson, Ida, Hadjisavvas, Helena, Hammonds, Fiona, Hantzi, Christina, Hauke, Marion, Haydock, Julie, Hayes, Orla, Nislev, Lizette Helbo, Hochstodter, Jessica, Hogg, Ashleigh, Hölbing, Manuela, Holland, Maureen, Holsbergen, Maartje, Howard, Linda, Hoyda, Aviya, Hull, Robert, Irish, Jane, Jackson, Wendy, Janssen, Wendy, Jeffrey, Lesley, Jourdan, Sofia, Jutrowska, Izabela, Kaniel, Chava, Karezos, Theofilos, Kelly, Niamh, Kelly, Jessica, Kennedy, Mary, Kennedy, Una, Kibaru, Joyce, Kirkman, Gemma, Klaproth, Janine, Kneese, Corinna, Koch, Andrea, Kokke, Kathleen, Koppelow, Martha, Krause, Sabine, Krauspe, Sabine, Kwakkenbos, Petra, Labarile, Nunzia, Lang, Hannah, Lassailly, Marianne, Leconte, Martine, Lepczynski, Linda, Levell, Emma, Levhar, Nina, Lindhort, Kerstin, Lisle, Jessica, Cauce, Beatriz Lopez, Lorenz, Gabriele, Lovati, Ambra, Lowry, Tracey, Lund, Margareta, Vorderbrügge, Anne Lutz, Maansson, Suzanne, Madapathage, Videsheka, Cheviakoff, Maelys, Magness, Alison, Manley, Orla, Manyoni, Catherine, Marg, Ingke, Marra, Antonella, Martins, Carole, Massella, Arianna, Mathias, Aurore, Mervyn, Danielle, Minsart, Charlotte, Mitchell, Sally, Monks, Kathleen, Montero, Mélanie, Moore, Alson, Moser, Maren, Moss, Alison, Mullen, Angela, Murciano, M. Francisca, Naylor, Deanna, Nehus, Ansgar, Nicholson, Anne, Nöding, Sarah, Nolan, Sinead, Nörenberg, Janet, Northcott, Clare, O'Connell, Jim, O’Kelly, Alison, Orbach-Zingboim, Noam, Orobitg, Judit, Otieno, Charlene, Owen, Charlotte, Patch, Sarah, Pauker, Maor, Pauli, Renate, Pearson, Harriet, Peggy, Falgon, Petit, Séverine, Petrissans, Christine, Piergallini, Simona, Pippard, Lucy, Pitt, Laura, Pócsik, Gabriella, Poher, Yoann, Pomes, Chloé, Pritchard, Lucy, Puchades, Laura, Quaid, Sheena, Rana, Aleem, Raynard, Dana, Reilly, Mykla, Reinert, Sonja, Reinknecht, Manuela, Renner, Baerbel, Reynolds, Rob, Rizzuto, Giulia, Robinson, Matthew, Robrechts, Joke, Rodriguez, Eva M., Rosenblum, Efrat, Russel, Tamlyn, Sadare, Ibiyemi, Salama, Noa, Schakel, Toos, Schauer, Anja, Schiavoni, Elisa, Shaw, Caroline, Shelton, Sarah, Sicart, Virginie, Siouville, Elodie, Smith, Orla, Soude, Théo, Stephenson, Sophie, Stephenson, Elaine, Steppe, Marjan, Sterkx, An, Stickley, Jo, Sugrue, Kathleen, Swietec, Natalia, Tasiaux, Charlotte, Thamu, Bhavneet, Thomas, Susane, Tobi, Ogwa, Touabi, Kahina, Tovi, Shifra, Tregonning, Julie, Turchini, Laura, Unkhoff, Julia, Unruh, Olesya, Uzun, Nurcan, Van Aert, Frauke, Bergh, Sandrine Vanden, Vandenbroucke, Louise, Vansteenkiste, Laura, Vardit, Shay, Vergriete, Valentin, Walker, Elaine, Warner, Eleanor, Watchorn, Olivia, Watson, Ekaterina, Wauthier, Marie-Claire, Weetman, Belgium Maria, Weston, Margaret, West-Petroschka, Wiebke, Wienecke, Susann, Wierling, Kerstin, Wiestler, Miriam, Wilcox, Rebecca, Wilhelmsen, Elva, Williams, Angharad, Williamson, Georgina, Wilson, Deborah, Wistance, Kate, Wortmann, Nicolas, Wurie, Subie, Yadgar, Karin, Young, Gail, Young, Megan, Aucouturier, Julien, Bertin, Marie- Jo, Bougrine, Hasnae, Coisnon, Marie, Defrance, Antoine, Gutierrez, Kati, Harouz, Amel, Jerber, Laure, Khlifi, Aida, Kirati, Amina, Liworo, Nasaladjine, Logoltat, Maude, Mailhat, Charlotte, M'Bayi, Chancely, Medane, Yasmina, Merkhoufa, Dalal, Elhad, Saouda Mohamed, Monthe, Bertille, Moyon, Fanny, Rabiega, Pascaline, Sekela, Jennifer, Thilloy, Charlotte, Hamamouche, Naima, Partisotti, Frederic, Blandin, Patrick, Mokhtari, Hocine, Coutard, Laure, and Doherty, Glen A.

Published
2023
Full Text
View/download PDF

7. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study.

Author

Ollech, Jacob E., Eran-Banai, Hagar, Goren, Idan, Fischler, Tali Sharar, Avni-Biron, Irit, Snir, Yifat, Broitman, Yelena, Cohen, Shaked, Friedenberg, Adi, Pauker, Maor H., Dotan, Iris, and Yanai, Henit

Subjects
ULCERATIVE colitis, SIGMOID colon, BIOTHERAPY, HEALING, COLITIS
Abstract

Introduction: Real-world data on tofacitinib's effectiveness is limited and mainly retrospective or registry-based. We elected to conduct a pragmatic prospective study to assess the efficacy of tofacitinib for moderate to severe ulcerative colitis (UC), aiming to evaluate the ability of intestinal ultrasound (IUS) to discriminate responders vs. non-responders in real-time. Methods: This pragmatic prospective clinical study included consecutive adult patients starting tofacitinib treatment for active moderate to severe UC. Patients were evaluated at baseline and after 8 weeks of tofacitinib (clinical, biomarker, endoscopy, and IUS). The primary outcome was clinical response defined by a decrease in the full Mayo score (fMS) of ≥3 at week 8. Next, we explored ultrasonographic parameters in the sigmoid colon as potential real-time classifiers to differentiate between responders and non-responders at week 8. Results: Overall, 30 adult patients started tofacitinib; the median age was 26.3 years (IQR 22.5-39.8), and 50% were female. Most patients (86.6%) had left-sided or extensive colitis, 96.7% had previously failed biologic therapy, and 60% (18/30) were on oral corticosteroids at the start of tofacitinib. At week 8, clinical response (a decrease in the fMS ≥ 3) and remission (fMS ≤ 2) rates were 40% (12/30) and 20% (6/30), respectively. Biomarker response (FC < 250 µg/g) and biomarker normalization (FC ≤ 100 µg/g) were achieved in 47.6% (10/21) and 38.1% (8/21) of patients, respectively. Endoscopic healing (endoscopic Mayo sub-score [EMS]≤1) was achieved in 33.3% (10/30) of patients. Sigmoid bowel wall normalization as assessed by IUS (sBWT ≤ 3) was achieved in 18.2% (4/22). The best sBWT cut-off at week 8 to accurately classify endoscopic healing vs. no healing was a sBWT of 3.6 mm (AUC of 0.952 [95% CI: 0.868-1.036], p < 0.001). Conclusion: In this real-world pragmatic prospective study, tofacitinib was an effective treatment for moderate to severe UC, and IUS at week 8 accurately discriminated treatment response from non-response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.

Author

Adamina, Michel, Minozzi, Silvia, Warusavitarne, Janindra, Buskens, Christianne Johanna, Chaparro, Maria, Verstockt, Bram, Kopylov, Uri, Yanai, Henit, Vavricka, Stephan R, Sigall-Boneh, Rotem, Sica, Giuseppe S, Reenaers, Catherine, Peros, Georgios, Papamichael, Konstantinos, Noor, Nurulamin, Moran, Gordon William, Maaser, Christian, Luglio, Gaetano, Kotze, Paulo Gustavo, and Kobayashi, Taku

Abstract

This article is the second in a series of two publications on the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn's disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also provides technical advice for a variety of common clinical situations. Both articles together represent the evidence-based recommendations of the ECCO for Crohn's disease and an update of prior ECCO Guidelines. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

Author

Edelman-Klapper, Hadar, Zittan, Eran, Bar-Gil Shitrit, Ariella, Rabinowitz, Keren Masha, Goren, Idan, Avni-Biron, Irit, Ollech, Jacob E., Lichtenstein, Lev, Banai-Eran, Hagar, Yanai, Henit, Snir, Yifat, Pauker, Maor H., Friedenberg, Adi, Levy-Barda, Adva, Segal, Arie, Broitman, Yelena, Maoz, Eran, Ovadia, Baruch, Golan, Maya Aharoni, Shachar, Eyal, Ben-Horin, Shomron, Perets, Tsachi-Tsadok, Ben Zvi, Haim, Eliakim, Rami, Barkan, Revital, Goren, Sophy, Navon, Michal, Krugliak, Noy, Werbner, Michal, Alter, Joel, Dessau, Moshe, Gal-Tanamy, Meital, Freund, Natalia T., Cohen, Dani, and Dotan, Iris

Published
2022
Full Text
View/download PDF

11. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel

Author

Avni-Biron, Irit, Bar-Gil Shitrit, Ariella, Koslowsky, Benjamin, Levartovsky, Asaf, Kopylov, Uri, Weisshof, Roni, Aviv Cohen, Nathaniel, Maharshak, Nitsan, Hovel, David, Israeli, Eran, Naftali, Timna, Goren, Idan, Snir, Yfat, Ollech, Jacob E., Banai-Eran, Hagar, Broitman, Yelena, Sharar-Fischler, Tali, Dotan, Iris, and Yanai, Henit

Published
2022
Full Text
View/download PDF

12. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial

Author

Yanai, Henit, Levine, Arie, Hirsch, Ayal, Boneh, Rotem Sigall, Kopylov, Uri, Eran, Hagar Banai, Cohen, Nathaniel A, Ron, Yulia, Goren, Idan, Leibovitzh, Haim, Wardi, Joram, Zittan, Eran, Ziv-Baran, Tomer, Abramas, Lee, Fliss-Isakov, Naomi, Raykhel, Barbara, Gik, Tamar Pfeffer, Dotan, Iris, and Maharshak, Nitsan

Published
2022
Full Text
View/download PDF

15. Early Indolent Course of Crohn’s Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable

Author

Yanai, Henit, Goren, Idan, Godny, Lihi, Maharshak, Nitsan, Ron, Yulia, Avni Biron, Irit, Leibovitzh, Haim, Banai Eran, Hagar, Aharoni Golan, Maya, Rabinowitz, Keren, Ziv Baran, Tomer, Lavie, Inbar, Yadgar, Karin, Zonensain, Keren, Kopylov, Uri, Ben Horin, Shomron, Eliakim, Rami, Waterman, Matti, Chowers, Yehuda, Ben-Shachar, Shay, and Dotan, Iris

Published
2021
Full Text
View/download PDF

16. The Role of Small-Bowel Capsule Endoscopy in the Diagnostic Algorithm of Complicated Perianal Disease.

Author

Avni-Biron, Irit, Toth, Ervin, Ollech, Jacob E., Nemeth, Artur, Johansson, Gabriele Wurm, Schweinstein, Hagai, Margalit, Reuma Yehuda, Kopylov, Uri, Dotan, Iris, and Yanai, Henit

Subjects
CROHN'S disease, CAPSULE endoscopy, CROSS-sectional imaging, SMALL intestine, CALPROTECTIN, INTESTINAL diseases
Abstract

Introduction: Complicated perianal disease (cPD) may be the sole presentation of Crohn's disease (CD). The role of small-bowel capsule endoscopy (SBCE) in the diagnostic algorithm of cPD is unclear. We aimed to evaluate the role of SBCE as a diagnostic tool, in patients with cPD, after a negative standard workup for CD. Methods: A multicenter, retrospective, cross-sectional study, in patients with cPD, and negative standard workup for CD (ileocolonoscopy and cross-sectional imaging), who underwent SBCE for suspected CD. Demographics, biomarkers, and the Lewis Score (LS) were recorded and analyzed. An LS ≥ 135 was considered a positive SBCE for diagnosing CD. Results: Ninety-one patients were included: 65 (71.4%) males; median age: 37 (29–51) years; cPD duration: 25.1 (12.5–66.1) months. Positive SBCE: 24/91 (26.4%) patients. Fecal calprotectin (FC) positively correlated with LS (r = 0.81; p < 0.001). FC levels of 100 µg/g and 50 µg/g had a sensitivity of only 40% and 55% to rule out small-bowel CD, with a negative predictive value (NPV) of only 76% and 80%, respectively. Conclusions: SBCE contributed to CD diagnosis in a quarter of patients with cPD after a negative standard workup. FC levels correlated with the degree of inflammation defined by the LS. However, the NPV of FC was low, suggesting that SBCE should be considered for patients with cPD even after a negative standard workup. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Discordant effects of ex-vivo JAK inhibition on inflammatory responses in colonic compared to ileal mucosa

Author

Kaboub, Kawsar, primary, Abu-Taha, Hanan, additional, Arrouasse, Jessica, additional, Shaham-Barda, Efrat, additional, Wasserberg, Nir, additional, Hayman-Manzur, Lucille, additional, Friedenberg, Adi, additional, Levy-Barda, Adva, additional, Goren, Idan, additional, Yanai, Henit, additional, Levi, Zohar, additional, Banai-Eran, Hagar, additional, Avni-Biron, Irit, additional, Ollech, Jacob E, additional, Cohen-Kedar, Sarit, additional, Dotan, Iris, additional, and Rabinowitz, Keren M, additional

Published
2024
Full Text
View/download PDF

18. Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study

Author

Ben-Horin, Shomron, Lahat, Adi, Amitai, Marianne M, Klang, Eyal, Yablecovitch, Doron, Neuman, Sandra, Levhar, Nina, Selinger, Limor, Rozendorn, Noa, Turner, Dan, Chowers, Yehuda, Odes, Shmuel, Schwartz, Doron, Yanai, Henit, Dotan, Iris, Braun, Tzipi, Haberman, Yael, Kopylov, Uri, and Eliakim, Rami

Published
2019
Full Text
View/download PDF

21. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study.

Author

Resál, Tamás, Bacsur, Péter, Keresztes, Csilla, Bálint, Anita, Bor, Renáta, Fábián, Anna, Farkas, Bernadett, Katsanos, Kostas, Michalopoylos, George, Ribaldone, Davide Giuseppe, Attauabi, Mohamed, Zhao, Mirabella, Barak, Hadar Amir, Yanai, Henit, Bezzio, Cristina, Rispo, Antonio, Castiglione, Fabiana, Shitrit, Ariella Bar-Gil, Pugliese, Daniela, and Armuzzi, Alessandro

Published
2024
Full Text
View/download PDF

23. Early Initiation of Adalimumab Significantly Diminishes Postoperative Crohn’s Disease Endoscopic Recurrence and Is Superior to 6-Mercaptopurine Therapy: An Open-Label, Randomized Controlled Study

Author

Hirsch, Ayal, primary, Scapa, Erez, additional, Fliss-Isakov, Naomi, additional, Tulchinsky, Hagit, additional, Itzkowitz, Eran, additional, Kariv, Yehuda, additional, Ron, Yulia, additional, Yanai, Henit, additional, White, Ian, additional, Yassin, Sharief, additional, Cohen, Nathaniel Aviv, additional, Brazovski, Eli, additional, Dotan, Iris, additional, and Maharshak, Nitsan, additional

Published
2023
Full Text
View/download PDF

24. Early Initiation of Adalimumab Significantly Diminishes Post-operative Crohn’s Disease Endoscopic Recurrence and Is Superior to 6-Mercaptopurine Therapy. An Open Label Randomized Controlled Study

Author

Hirsch, Ayal, primary, Scapa, Erez, additional, Fliss Isakov, Naomi, additional, Tulchinsky, Hagit, additional, Itzkowitz, Eran, additional, Kariv, Yehuda, additional, Ron, Yulia, additional, Yanai, Henit, additional, White, Ian, additional, Yassin, Sharif, additional, Cohen, Nathaniel Aviv, additional, Brazovski, Eli, additional, Dotan, Iris, additional, and Maharshak, Nitsan, additional

Published
2023
Full Text
View/download PDF

25. A Real-World Prospective Cohort Study of Patients With Newly Diagnosed Crohn’s Disease Treated by a Multidisciplinary Team: 1-Year Outcomes

Author

Yanai, Henit, primary, Sharar Fischler, Tali, additional, Goren, Idan, additional, Eran-Banai, Hagar, additional, Ollech, Jacob E, additional, Snir, Yifat, additional, Broitman, Yelena, additional, Barkan, Revital, additional, Pfeffer-Gik, Tamar, additional, Godny, Lihi, additional, Kutokov, Yelena, additional, Friedeberg, Adi, additional, Pauker, Maor H, additional, Rabinowitz, Keren Masha, additional, Avni-Biron, Irit, additional, and Dotan, Iris, additional

Published
2023
Full Text
View/download PDF

27. Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

Author

Edelman-Klapper, Hadar, primary, Rabinowitz, Keren Masha, additional, Zittan, Eran, additional, Bar-Gil Shitrit, Ariella, additional, Goren, Idan, additional, Avni-Biron, Irit, additional, Ollech, Jacob E., additional, Lichtenstein, Lev, additional, Banai-Eran, Hagar, additional, Yanai, Henit, additional, Snir, Yifat, additional, Pauker, Maor H., additional, Friedenberg, Adi, additional, Levy-Barda, Adva, additional, Broitman, Yelena, additional, Ben Zvi, Haim, additional, Perets, Tsachi-Tsadok, additional, Eliakim, Rami, additional, Barkan, Revital, additional, Goren, Sophy, additional, Cohen, Dani, additional, and Dotan, Iris, additional

Published
2023
Full Text
View/download PDF

29. Shackling incarcerated people in Israeli hospitals—a multicentre study followed by a national intervention programme

Author

Bar, Nitai, primary, Naaman, Efrat, additional, Rosin, Danny, additional, Aviram, Eliad, additional, Yanai, Henit, additional, Yehudai, Noam, additional, Walden, Raphael, additional, Padova, Hagit, additional, Kori, Michal, additional, Peled-Raz, Maya, additional, Tedgi, Dalya, additional, Kabha, Eyad, additional, Yerushalmi, Baruch, additional, Gil, Ziv, additional, Wagner, Nurit, additional, Karni, Tamar, additional, and Turner, Dan, additional

Published
2023
Full Text
View/download PDF

32. Mesenchymal stem cell therapy for Crohn's perianal fistula—a real‐world experience.

Author

White, Ian, Yanai, Henit, Avni, Irit, Slavin, Moran, Naftali, Timna, Tovi, Shifra, Dotan, Iris, and Wasserberg, Nir

Subjects
*MESENCHYMAL stem cells, *STEM cell treatment, *CROHN'S disease, *STEM cell transplantation, *DISEASE remission, *ANAL diseases, *FISTULA
Abstract

Aim: Remission rates of medically and surgically treated complex perianal fistulas in Crohn's disease are low. Recently, trials have demonstrated the potential for long‐term remission with local injection of allogeneic adipose‐derived mesenchymal stem cells (darvadstrocel). Our aim was to analyse outcomes from our real‐world experience with this new treatment. Methods: All patients with Crohn's disease suffering complex perianal fistulas who consecutively underwent administration of darvadstrocel at two centres were followed up and evaluated. Patients were assessed for clinical remission, response, failure, and any complications during follow‐up. The results of all patients with a minimum of 3 months' follow‐up are presented. Results: Thirty‐three patients with Crohn's disease and complex perianal fistulas were included. Of these, 20 (61%) experienced clinical remission that was maintained for a mean follow‐up of 14 (3–32) months. A total of 24 of 33 (73%) experienced at least 3 months of clinical remission, with four later having recurrence (3–12 months). Among the remaining nine patients who did not experience clinical remission, two (6%) had partial remission (such as one of two fistulas closing), two (6%) showed signs of response but not remission, and five (15%) showed no signs of healing. The mean time to maintained clinical remission was 6 weeks (range 2 weeks to 6 months), and there were no severe adverse events. Conclusion: In this real‐world experience, treatment of Crohn's disease complex perianal fistulas with darvadstrocel had a 61% success rate for maintained clinical remission. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Real‐world experience with Curcumin–QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study

Author

Yanai, Henit, primary, Salomon, Nir, additional, Lahat, Adi, additional, Ungar, Bella, additional, Eliakim, Rami, additional, Kriger‐Sharabi, Ofra, additional, Reiss‐Mintz, Hilla, additional, Koslowsky, Benjamin, additional, Shitrit, Ariella Bar‐Gil, additional, Tamir‐Degabli, Natalie, additional, Dotan, Iris, additional, Zittan, Eran, additional, Maharshak, Nitsan, additional, Hirsch, Ayal, additional, Ben‐Horin, Shomron, additional, and Kopylov, Uri, additional

Published
2023
Full Text
View/download PDF

36. Thiopurines have longer treatment durability than methotrexate in adults and children with Crohn's Disease: a nationwide analysis from the epi-IIRN cohort

Author

Atia, Ohad, primary, Friss, Chagit, additional, Ledderman, Natan, additional, Greenfeld, Shira, additional, Kariv, Revital, additional, Daher, Saleh, additional, Yanai, Henit, additional, Loewenberg Weisband, Yiska, additional, Matz, Eran, additional, Dotan, Iris, additional, and Turner, Dan, additional

Published
2023
Full Text
View/download PDF

38. Prevalence and Outcomes of No Treatment Versus 5-ASA in Ulcerative Colitis: A Nationwide Analysis From the epi-IIRN

Author

Atia, Ohad, primary, Magen Rimon, Ramit, additional, Ledderman, Natan, additional, Greenfeld, Shira, additional, Kariv, Revital, additional, Loewenberg Weisband, Yiska, additional, Shaoul, Ron, additional, Matz, Eran, additional, Odes, Shmuel, additional, Goren, Idan, additional, Yanai, Henit, additional, Dotan, Iris, additional, and Turner, Dan, additional

Published
2023
Full Text
View/download PDF

39. CURCUMIN-QINGDAI COMBINATION FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED CLINICAL TRIAL

Author

Ben-Horin, Shomron, primary, Salomon, Nir, additional, Karampekos, Georgios, additional, Viazis, Nikos, additional, Lahat, Adi, additional, Ungar, Bella, additional, Eliakim, Rami, additional, Kriger-Sharabi, Ofra, additional, Reiss-Mintz, Hilla, additional, Yanai, Henit, additional, Dotan, Iris, additional, Zittan, Eran, additional, Hirsch, Ayal, additional, Maharshak, Nitsan, additional, Mantzaris, Gerassimos, additional, and Kopylov, Uri, additional

Published
2023
Full Text
View/download PDF

40. I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease

Author

Peyrin-Biroulet, Laurent, Rahier, Jean-François, Kirchgesner, Julien, Abitbol, Vered, Sebastian, Shaji, Armuzzi, Alessandro, Karmiris, Konstantinos, Gisbert, Javier P., Bossuyt, Peter, Helwig, Ulf, Burisch, Johan, Yanai, Henit, Doherty, Glen A., Magro, Fernando, Molnar, Tamás, Löwenberg, Mark, Halfvarson, Jonas, Zagorowicz, Edyta, Rousseau, Hélène, Baumann, Cédric, Baert, Filip, Beaugerie, Laurent, Peyrin-Biroulet, Laurent, Rahier, Jean-François, Kirchgesner, Julien, Abitbol, Vered, Sebastian, Shaji, Armuzzi, Alessandro, Karmiris, Konstantinos, Gisbert, Javier P., Bossuyt, Peter, Helwig, Ulf, Burisch, Johan, Yanai, Henit, Doherty, Glen A., Magro, Fernando, Molnar, Tamás, Löwenberg, Mark, Halfvarson, Jonas, Zagorowicz, Edyta, Rousseau, Hélène, Baumann, Cédric, Baert, Filip, and Beaugerie, Laurent

Abstract

BACKGROUND AND AIMS: There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE was to assess prospectively safety concerns in IBD, with specific focus on the risk of cancer/lymphoma and serious infections in patients treated with for anti-tumor necrosis factor and other biologics monotherapy as well as in combination with immunomodulators. METHODS: I-CARE was designed as a European prospective longitudinal observational multicenter cohort study, to include patients with a diagnosis of Crohn's disease, ulcerative colitis or IBD unclassified established at least 3 months prior to enrollment. RESULTS: A total of 10,206 patients were enrolled between March 2016 and April 2019, including 6,169 (60.4%) patients with Crohn's disease, 3,853 (37.8%) with ulcerative colitis, and 184 (1.8%) with a diagnosis of IBD unclassified. Thirty-two percent of patients were receiving AZA/thiopurines, 4.6% 6-mercaptopurine, and 3.2% methotrexate at study entry. At inclusion, 47.3% of patients were treated with an anti-tumor necrosis factor agent, 8.8% with vedolizumab, and 3.4% with ustekinumab. Roughly one quarter of patients (26.8%) underwent prior IBD related surgery. Sixty-six % of patients had been previously treated with systemic steroids. Three percent of patients had a medical history of cancer prior to inclusion, and 1.1% had a history of colonic, esophageal or uterine cervix high-grade dysplasia. CONCLUSION: I-CARE is an ongoing investigator-initiated observational European prospective cohort study that will provide unique information on the long-term benefits and risks of biological therapies in IBD patients.

Published
2023
Full Text
View/download PDF

41. Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study

Author

Albshesh, Ahmad; https://orcid.org/0000-0001-8962-4263, Bannon, Lian; https://orcid.org/0000-0002-5317-3613, Sharar Fischler, Tali, Truyens, Marie, Vavricka, Stephan R, Tepes, Katja; https://orcid.org/0000-0002-6131-0059, Pugliese, Daniela; https://orcid.org/0000-0001-7930-5402, Savarino, Edoardo V; https://orcid.org/0000-0002-3187-2894, Zittan, Eran, Drobne, David; https://orcid.org/0000-0003-2734-675X, Roblin, Xavier, Bar-Gil Shitrit, Ariella, Armuzzi, Alessandro; https://orcid.org/0000-0003-1572-0118, Lobaton, Triana; https://orcid.org/0000-0003-1817-7704, Maharshak, Nitsan, Yanai, Henit; https://orcid.org/0000-0001-5483-5271, Ben-Horin, Shomron, Kopylov, Uri, Albshesh, Ahmad; https://orcid.org/0000-0001-8962-4263, Bannon, Lian; https://orcid.org/0000-0002-5317-3613, Sharar Fischler, Tali, Truyens, Marie, Vavricka, Stephan R, Tepes, Katja; https://orcid.org/0000-0002-6131-0059, Pugliese, Daniela; https://orcid.org/0000-0001-7930-5402, Savarino, Edoardo V; https://orcid.org/0000-0002-3187-2894, Zittan, Eran, Drobne, David; https://orcid.org/0000-0003-2734-675X, Roblin, Xavier, Bar-Gil Shitrit, Ariella, Armuzzi, Alessandro; https://orcid.org/0000-0003-1572-0118, Lobaton, Triana; https://orcid.org/0000-0003-1817-7704, Maharshak, Nitsan, Yanai, Henit; https://orcid.org/0000-0001-5483-5271, Ben-Horin, Shomron, and Kopylov, Uri

Abstract

BACKGROUND The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. AIMS AND METHODS In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in patients with Crohn's disease (CD) who failed VDZ as a first-line treatment. The primary outcome was clinical response at week 16-22. Secondary outcomes included the rates of clinical remission, steroid-free clinical remission, CRP normalization, and adverse events. RESULTS Fifty-nine patients who failed on VDZ as a first-line treatment for CD were included; 52.8% patients received anti-TNF and 47.2% UST as a second-line therapy. In initial period (Week 16-22), the clinical response and remission rate was similar between both groups: 61.2% vs. 68%, p = 0.8 and 48.3% vs. 56%, p = 0.8 on anti-TNF and UST therapy, respectively. Furthermore, in the maintenance period the rate was similar: 75% vs. 82.3%, p = 0.8 and 62.5% vs. 70.5%, p = 0.8, respectively. Of the patients, 12 out of the 59 stopped the therapy, without a significant difference between the two groups (p = 0.6). CONCLUSION Second-line biological therapy after VDZ failure therapy was effective in >60% of the patients with CD. No differences in effectiveness were detected between the use of anti-TNF and UST as a second line.

Published
2023

45. Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Author

Albshesh, Ahmad, primary, Bannon, Lian, additional, Sharar Fischler, Tali, additional, Truyens, Marie, additional, Vavricka, Stephan R., additional, Tepes, Katja, additional, Pugliese, Daniela, additional, Savarino, Edoardo V., additional, Zittan, Eran, additional, Drobne, David, additional, Roblin, Xavier, additional, Bar-Gil Shitrit, Ariella, additional, Armuzzi, Alessandro, additional, Lobaton, Triana, additional, Maharshak, Nitsan, additional, Yanai, Henit, additional, Ben-Horin, Shomron, additional, and Kopylov, Uri, additional

Published
2023
Full Text
View/download PDF

46. 5‐aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease—A nationwide cohort study

Author

Atia, Ohad, primary, Goren, Idan, additional, Fischler, Tali Sharar, additional, Weisband, Yisca Loewenberg, additional, Greenfeld, Shira, additional, Kariv, Revital, additional, Ledderman, Natan, additional, Matz, Eran, additional, Rimon, Ramit Magen, additional, Dotan, Iris, additional, Turner, Dan, additional, and Yanai, Henit, additional

Published
2023
Full Text
View/download PDF

47. QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE

Author

Kopylov, Uri, primary, Salomon, Nir, additional, Zittan, Eran, additional, Lahat, Adi, additional, Eliakim, Rami, additional, Weiss, Batia, additional, Koslowsky, Benjamin, additional, Gil, Ariella Shitrit-Bar, additional, Saban, Lotem, additional, Maharshak, Nitsan, additional, Hirsch, Ayal, additional, Ritter, Einat, additional, Shahar, Eyal, additional, Tamir, Natalie, additional, Dotan, Iris, additional, Ben-Horin, Shomron, additional, and Yanai, Henit, additional

Published
2023
Full Text
View/download PDF

49. Newly Diagnosed Crohn’s Disease Patients in India and Israel Display Distinct Presentations and Serological Markers: Insights from Prospective Cohorts

Author

Goren, Idan, primary, Sharar Fischler, Tali, additional, Yanai, Henit, additional, Pal, Partha, additional, Adigopula, Bhargavi, additional, Pendyala, Sushmitha, additional, Ganesh, Girish, additional, Vishnubhotla, Ravikanth, additional, Rabinowitz, Keren Masha, additional, Shaham Barda, Efrat, additional, Yadamreddy, Durga, additional, Godny, Lihi, additional, Peleg, Noam, additional, Banerjee, Rupa, additional, and Dotan, Iris, additional

Published
2022
Full Text
View/download PDF

50. Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease

Author

Ellul, Pierre, primary, Schembri, John, additional, Vella Baldacchino, Andrea, additional, Molnár, Tamas, additional, Resal, Tamas, additional, Allocca, Mariangela, additional, Furfaro, Federica, additional, Dal Buono, Arianna, additional, Theodoropoulou, Angeliki, additional, Fragaki, Maria, additional, Tsoukali, Emmanouela, additional, Mantzaris, Gerassimos J, additional, Phillips, Frank M, additional, Radford, Shellie, additional, Moran, Gordon, additional, Gonzalez, Haidee, additional, Sebastian, Shaji, additional, Fousekis, Fotios, additional, Christodoulou, Dimitrios, additional, Snir, Ifat, additional, Lerner, Zlata, additional, Yanai, Henit, additional, Michalopoulos, Georgios, additional, Tua, Julia, additional, Camilleri, Liberato, additional, Papamichael, Kostas, additional, Karmiris, Konstantinos, additional, and Katsanos, Konstantinos, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results